Therapeutic treatment methods
US7547687B2 · kind B2 · utility
32Cited by
14References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 12, 2007 |
| Grant date | Jun 16, 2009 |
| Priority date | — |
| Expiry date | Jun 5, 2027 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P19/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.